Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
University Of Hong Kong Versitech Limited currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This prosecution activity is limited to 1 distinct examiner and 1 distinct art unit, reflecting a targeted approach for this specific filing. The placement within the biotechnology sector indicates that the pending application likely involves biological or medicinal research.
The busiest examiner, RZECZYCKI, PHILLIP MATTHEW, is managing 1 busiest examiner pending action. Because the company has only 1 pending action, the prosecution timeline is tied to the workload and review pace of this examiner. Practitioners should monitor the specific trends within the 1 art unit to better anticipate the examiner's requirements. This focused portfolio structure allows for a dedicated response strategy to the 1 pending action without the need to balance competing priorities across examiners or technology areas. The university can leverage the expertise of the 1 distinct examiner to navigate the Biotechnology & Pharmaceuticals review process.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RZECZYCKI, PHILLIP MATTHEW | 1 | 64.8% | +37.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18316254 | COMPOUNDS AFFECTING PIGMENT PRODUCTION AND METHODS FOR TREATMENT OF BACTERIAL DISEASES | RZECZYCKI, PHILLIP MATTHEW | — |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18316254 | COMPOUNDS AFFECTING PIGMENT PRODUCTION AND METHODS FOR TREATMENT OF BACTERIAL DISEASES | RZECZYCKI, PHILLIP MATTHEW | 1625 | §112 | Final Rejection | — | Pending | May 12, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUniversity Of Hong Kong Versitech Limited has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Phillip Matthew Rzeczycki has the most, with 1 of University Of Hong Kong Versitech Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
